This blend combines:
- CJC-1295 DAC – a 29-amino-acid GHRH analog engineered with Drug Affinity Complex (DAC) technology for extended plasma half-life (~6–8 days) via reversible albumin binding.
- Ipamorelin – a selective 5-amino-acid ghrelin receptor agonist that elicits acute, pulsatile GH release with high specificity and minimal impact on cortisol, prolactin, or ACTH.
Together, the components enable modeling of physiological GH patterns: prolonged baseline elevation from CJC-1295 DAC complemented by discrete, high-amplitude pulses from Ipamorelin—widely regarded as the reference standard for GH axis synergy studies in aging, sarcopenia, metabolic, and recovery research models since the mid-2000s.
Key Scientific Features
- ≥98% purity for both CJC-1295 DAC and Ipamorelin, verified by HPLC and mass spectrometry.
- Confirmed sequences: CJC-1295 DAC (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH₂); Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂).
- Lyophilized in dual-vial or pre-mixed format for optimal stability and reconstitution flexibility.
- Full batch-specific Certificate of Analysis documenting purity, identity, content, and blend ratio.
- Synthesized in GMP-aligned, ISO-compliant facilities.
- Suited to long-acting GHRH + selective GHS-R1a agonist research protocols.
Research-Referenced Attributes (Pre-clinical literature observations; no therapeutic claims)
- Pre-clinical models show CJC-1295 administration produces dose-dependent GH increases (2–10× baseline) lasting up to 6 days and IGF-1 elevation (1.5–3×) persisting 9–11 days post-dose (PMID: 16352683).
- In GHRH-knockout models, CJC-1295 restores GH axis function, normalizes body composition, and supports growth parameters with infrequent dosing (PMID: 16822960).
- Ipamorelin induces potent, selective GH secretion in pituitary cultures and animal systems without meaningful elevation of cortisol, prolactin, or ACTH (PMID: 9849822).
- Combined application in experimental paradigms yields synergistic GH output characterized by rapid pulsatile onset (Ipamorelin) layered on sustained elevation (CJC-1295 DAC), providing a robust platform for axis dynamics and IGF-1 pathway studies.
Why Researchers Select Nationwide Peptides CJC-1295 + Ipamorelin Blend
- Most widely referenced and requested GH synergy combination in the global research community.
- Matches published clinical/research sequences with standard 1:1 ratio or custom blends available.
- Highest available analytical transparency: full HPLC/MS data, third-party CoA per batch.
- Trusted sourcing for endocrinology, metabolism, aging, and performance physiology laboratories.
- Competitive catalog options: 5 mg + 5 mg, 10 mg + 10 mg, and bulk research volumes.
For Research Use Only. This product is supplied strictly for in vitro and in vivo laboratory investigations by qualified researchers in controlled experimental settings. Statements regarding this product have not been evaluated by the FDA. It is not intended for human consumption, injection, diagnostic use, therapeutic application, or any non-research purpose.
Advance Your GH Synergy Investigations
Select the CJC-1295 + Ipamorelin blend formulated for reproducibility and precision in pre-clinical somatotropic research. Current limited batches maintain verified ≥98% purity.
